A vision of cell death: Insights into immune privilege

Immunological Reviews

Volumn 156, Issue , 1997, Pages 167-184

  Ferguson, Thomas A ^a   Griffith, Thomas S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN; CELL DEATH; EYE; GENITAL SYSTEM; IMMUNE RESPONSE; INFLAMMATION; LYMPHOID CELL; PRIORITY JOURNAL; REVIEW;

EID: 0030951069     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1997.tb00967.x     Document Type: Review

References (86)

1. Van Dooremaal JC. Die Entwickelung der in fremden Grund versetzten lebenden Gewebe. Albrecht von Griefe's Arch Ophthalmol 1873;19:359-373.
2. Medawar PB. Immunity to homologous grafted skin. III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 1948;29:58-69.
3. Greene HSN. Heterologous transplantation of the Brown-Pearce Tumor. Cancer Res 1949;9:728-935.
4. Hooper P, Bora N, Kaplan HJ, Ferguson TA. Inhibition of lymphocyte proliferation by resident ocular cells. Curr Eye Res 1991;10:363-372.
5. Wilbanks G, Streilein JW. Fluids from immune privileged sites endow macrophages with the capacity to induce antigen-specific immune deviation via a mechanism involving transforming growth factor-β. Eur J Immunol 1992;22:165-174.
6. Ferguson TA, Fletcher S, Herndon JM, Griffith TS. Neuropeptides modulate immune deviation induced via the anterior chamber of the eye. J Immunol 1995;155:1746-1756.
7. + cells in the murine iris. Invest Ophthal Vis Sci 1991;32:2423-2431.
8. Bora NS, Gobelman CL, Atkinson JP, Pepose JS, Kaplan HJ. Differential expression of the complement regulatory proteins in the human eye. Invest Ophthal Vis Sci 1993;34:3579-3584.
9. Apte R, Niederkorn JY. Isolation of a unique natural killer cell inhibitory factor present in the anterior chamber of the eye. J Immunol 1996;156:2667-2673.
10. Ferguson TA, Herndon JM, Dube P. The immune response and the eye. IV. A role for tumor necrosis factor in anterior chamber associated immune deviation. Invest Ophthal Vis Sci 1994;35:2643-2651.
11. Ferguson T, Waldrep JC, Kaplan HJ. The immune response and the eye. II. The nature of T suppressor cell induction in anterior chamber associated immune deviation (ACAID). J Immunol 1987;139:352-357.
12. Kaplan HJ, Streilein JW. Immune response to immunization via the anterior chamber of the eye: I. F1-lymphocyte induced immune deviation. J Immunol 1977;118:809-814.
13. Sonoda Y, Streilein JW. Impaired cell mediated immunity (ACAID) in mice bearing healthy orthotopic corneal allografts. J Immunol 1993;150:1727-1734.
14. Joo C-K, Pepose JS, Laycock KA, Stuart PM. Allogeneic graft rejection in a murine model of orthotopic corneal transplantation. In: Nussenblat t RB, Whitcup SM, Caspi RR, Gery I, editors. Advances in ocular immunology. Elsevier Science B. V. 1994;115-118.
15. Whittum-Hudson J, Farazdaghi M, Prendergast RA. A role for T lymphocytes in preventing experimental herpes simplex type 1 retinitis. Invest Ophthal Vis Sci 1985;26:1524-1532.
16. Wetzig RP, Foster S, Greene MI. Ocular immune responses. I. Priming of A/J mice in the anterior with azobenzenearsonate-derivatized cells induces second-order-like suppressor T-cells. J Immunol 1982;128:1753-1759.
17. Niederkorn JY, Streilein JW. Alloantigens placed into the anterior chamber of the eye induce specific suppression of delayed type hypersensitivity but normal cytotoxic T lymphocyte responses. J Immunol 1983;131:2587-2594.
18. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270:1189-1192.
19. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke, RC. A role for CD95 ligand in preventing graft rejection. Nature 1995;377:630-632.
20. Mogil RJ, et al. Fas (CD95) participates in peripheral T cell deletion and associated apoptosis in vivo. Int Immunol 1995;7:1451-1458.
21. Singer GG, Abbas AK. The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1995;1:365-371.
22. Nagata S, Suda T. Fas and Fas ligand. lpr and gld mutations. Immunol Today 1995;16:39-43.
23. 2+-independent T cell-mediated cytotoxicity. J Exp Med 1993;177:195-200.
24. Abbas, AK. Die and let live. Eliminating dangerous lymphocytes. Cell 1996;84:655-657.
25. Martin SJ, et al. Early redistribution of plasma membrane phosphatidyserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of bcl-2 and abl. J Exp Med 1995;182:1545-1556.
26. Nagata S, Golstein P. Fas the death factor. Science 1995;267:1449-1456.
27. Suda T, et al. Expression of the fas ligand in cells of T cell lineage. J Immunol 1995;154:3806-3813.
28. Ju S-T, et al. Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995;373:444-448.
29. Owen-Schaub LB, Tonehara S, Crump WL, Grimm EA. DNA fragementation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. Cell Immunol 1992;140:197-205.
30. Tanaka M, et al. Fas ligand in human serum. Nature Medicine 1996;2:317-332.
31. Hendricks RL, Janowicz M, Tumpey TM. Critical role of corneal Langerhans cells in the CD4- but not CD8-mediated immunopathology in herpes simplex virus-1-infected mouse corneas. J Immunol 1992;148:2522-2529.
32. Rizzo LV, et al. Establishment and characterization of a murine CD4+ T cell line and clone that induce experimental autoimmune uveoretinitis in B10.A mice. J Immunol 1996;156:1654-1660.
33. L. Immunity 1995;3:87-98.
34. Friesen C, Herr I, Krammer PH, Devatin K-M. Involvement of CD95 (APO-1/Fas) receptro/ligand system in drug-induced aopotosis in leukemic cells. Nature Medicine 1996;2:574-577.
35. Brunner T, et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995;373:441-444.
36. French LE, et al. Fas and Fas ligand in embryos and adult mice: Ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 1996;133:335-343.
37. Billingham RE, Silvers WK. Studies on cheek pouch skin homografts in the syrian hamster. Ciba Foundation Symposium on Transplantation 1962;90-108.
38. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counter attach: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996;184:1075-1082.
39. Sieg S, et al. Herpes simplex virus inhibition of Fas ligand expression. J Virol 1996;70:8747-8751.
40. Lenardo MJ. Interleukin-2 programs mouse αβ T lymphocytes for apoptosis. Nature 1991;353:858-861.
41. Grell M, Krammer P, Scheurich P. Segregation of APO-1/Fas antigen and tumor necrosis factor receptor mediated apoptosis. Eur J Immunol 1991;24:2563-2566.
42. Um HD, Orenstein JM, Wahl SM. Fas mediates apoptosis in human monocytes by a reactive oxygen intermediate dependent pathway. J Immunol 1996 156:3469-3477.
43. Griffith TS, Yu X, Herndon JM, Green DR. Ferguson TA. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity 1996;5:7-16.
44. Li X-Y, D'Orazio T. Niederkorn JY. Role of Th1 and Th2 cell in anterior chamber associated immune deviation. Immunol 1996;89:34-40.
45. Dorf ME, Benacerraf B. Suppressor cells and immunoregulation. Ann Rev Immunol 1984;2:27-58.
46. Ramsdell F, Seaman MS, Miller RE, Picha KS, Kennedy MK, Lynch DH. Differential ability of Th1 and Th2 T-cells to undergo activation-induced cell death. Int Immunol 1994;6:1545-1553.
47. Thompson CB. Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell 1995;81:979-982.
48. Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993;151:1224-1231.
49. Streilein JW, Niederkorn JY. Induction of anterior chamber associated immune deviation requires an intact, functional spleen. J Exp Med 1981;153:1058.
50. Streilein JW, Atherton SS, Vann V. A critical role for ACAID in the distinctive pattern of retinitis that follows anterior chamber inoculation of HSV-1. Curr Eye Res 1987;6:127-131.
51. Griffith TS, Herndon JM, Lima J, Kahn M, Ferguson TA. The immune response and the eye. T-cell receptor α-chain related molecules regulate the systemic immunity to antigen presented via the anterior chamber of the eye. Int Immunol 1995;7:1617-1625.
52. Ferguson T, Hayashi J, Kaplan H. The immune response and the eye. III. Anterior chamber associated immune deviation can be adoptively transferred by serum. J Immunol 1985;143:821-826.
53. Wilbanks G, Mammolenti M, Streilein JW. Studies on the induction of anterior chamber-associated immune deviation (ACAID) II. Eye-derived cells participate in generating bloodborne signals that induce ACAID. J Immunol 1991;146:3018-3023.
54. Ferguson TA, Herndon JM. The immune response and the eye. V. The ACAID inducing signal is dependent on the nature of the antigen. Invest Ophthal Vis Sci 1994;35:3085-3093.
55. Shin J, Lee S, Stominger J. Translocation of TCRα chains into the lumen of the endoplasmic reticulum and their degradation. Science 1993;259:1901-1905.
56. + T cells expressing Vβ8 TCR: A role of the Qa-1 molecule. Immunity 1995;2:185-194.
57. Vandenbark AA, Hashim G, Offner H. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature 1989;341:541-545.
58. Offner H, Hashim GA, Vandenbark AA. T cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis. Science 1991;251:430-433.
59. Cohen I, Weiner HL. T-cell vaccination. Immunol Today 1988;9:332-336.
60. Cousins S, Trattler W, Streilein J. Immune privilege and suppression of immunogenic inflammation in the anterior chamber of the eye. Curr Eye Res 1991;10:287-293.
61. Hara Y, Caspi R, Wiggert B, Dorf ME., Streilein JW. Analysis of an in vitro generated signal that induces systemic immune deviation similar to that elicited by antigen injected into the anterior chamber of the eye. J Immunol 1992;149:1531-1536.
62. Pernow, B. Substance P. Pharmol Rev 1983;35:85-120.
63. Bill A, Stjernschantz J, Mandahl A, Brodin E, Nilsson G. Substance P release on trigeminal nerve stimulation. Effects on the eye. Acta Physiolog Scand 1976;106:371-375.
64. Martin FC, Charles AC, Sanderson MJ, Merrill JE. Substance P stimulates IL-1 production by astrocytes via intracellular calcium. Brain Research 1992;599:13-18.
65. Shadiack AM, Hart RP, Carlson CD, Jonakait GM. Interleukin-1 induces substance P in sympathetic ganglia through the induction of leukemia inhibitory factor (LIF). Journal of Neuroscience 1993;13:2601-2606.
66. Pascual DW, Bost KL. Substance P production by P388D1 macrophages: a possible autocrine function for this neuropeptide. Immunol 1990;71:52-58.
67. Beckers H, Klooster J, Vrensen G, Lamers W. Substance P in the rat cornea and iridial nerves: an ultrastructural immunohistochemical study. Ophthalmic Res 1993;25:192-196.
68. Okamoto Y, et al. Cytokine expression after topical administration of substance P to human nasal mucosa. The role of substance P in nasal allergy. J Immunol 1993;151:4391-4396.
69. Gutwald J, Goebeler M, Sorg C. Neuropeptides enhance irritant and allergic contact dermatitis. Journal of Investigative Dermatology 1991;96:695-672.
70. Wershil BK, et al. Variants of vasoactive intestinal peptide in mouse mast cells and rat basophilic leukemia cells. Cell Immunol 1993;151:369-375.
71. Ottaway CA. Insertion and internalization of vasoactive intestinal peptide (VIP) receptors in murine CD4 T lymphocytes. Regulatory Peptides. 1992;41:49-59.
72. Flugel C, Tamm ER, Mayer B, Lutjen-Drecoll E. Species differences in choroidal vasodilative innervation: Evidence for specific intrinsic nitrergic and VIP-positive neurons in the human eye. Invest Ophthal Vis Sci 1994;35:592-599.
73. Sun L, Ganea D. Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production through different molecular mechanisms in T cells activated via the T cell receptor/CD3 complex. J Neuroimmunol 1993;48:59-65.
74. Muscettola M, Grasso G. Somatostatin and vasoactive intestinal peptide reduce interferon gamma production by human peripheral blood mononuclear cells. Immunobiol 1990;180:419-425.
75. Moore TC, Spruck CH, Said SI. In vivo depression of lymphocyte traffic in sheep by VIP and HIV (AIDS)-related peptides. Immunopharm 1988;16:181-187.
76. Taylor A, Streilein JW, Cousins SW. Immunoreactive VIP contributes to immunosuppressive activity of normal aqueous humor. J Immunol 1994;153:1080-1087.
77. Ferguson TA, Hayashi J, Kaplan H. Regulation of the systemic immune response by visible light and the eye. FASEB J. 1988;2:3017-3021.
78. Kahn M, Kaplan H, Ferguson T. Retinal necrosis and immune response following anterior chamber inoculation of herpes simplex virus type-1 are regulated by light. Arch Virol 1993;131:115-122.
79. Lau HT, Yu M, Fontana A, Stoeckert CJ Jr. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996;273:109-112.
80. Stuart PM, Griffith TS, Usui N, Pepose JS, Yu X, Ferguson TA. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest 1997;99:396-402.
81. Brady SE, Rapuano JC, Arentsen JJ, Cohen EJ, Laibson PR. Clinical indications and procedures associated with penetrating keratoplasty. Am J Ophthalmol 1989;108:118-122.
82. Niederkorn JY, Callahan D, Ross JR. Prevention of the induction of allospecific cytotoxic T lymphocyte and delayed hypersensitivity responses by ultraviolet irradiation of corneal allografts. Transplantation 1990;50:281-286.
83. Ferguson TA, Dube P, Griffith TS. Regulation of contact hypersensitivity by IL-10. J Exp Med 1994;179:1597-1603.
84. Ma D, Niederkorn JY. Transforming growth factor-β down-regulates major histocompatibihty complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis. Immunol 1995;86:263-269.
85. Streilein JW, Wilbanks G, Cousins S. Immunoregulatory mechanisms of the eye. J Neuroimmunol 1992;39:185-195.
86. Ljunggren H, Kärre K. In search of the "missing self": MHC molecules and NK function. Immunol Today 1990;11:237-239.